Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | TYK2 | P29597 | 4/20 | 0.52 |
| ▸ | JAK1 | P23458 | 3/20 | 0.52 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368235 | 0.86 | JAK2 (0.55) | JAK2TYK2JAK1ANO1MEN1 | |
| SCHEMBL30368230 | 0.82 | JAK2 (0.62) | JAK2TYK2JAK1ANO1 | |
| SCHEMBL30368210 | 0.81 | ANO1 (0.65) | JAK2TYK2JAK1ANO1ALDH1A1 | |
| SCHEMBL30368259 | 0.79 | ANO1 (0.66) | JAK2TYK2JAK1ANO1NR3C2 | |
| SCHEMBL30368170 | 0.79 | ANO1 (0.51) | JAK2TYK2JAK1ANO1NPC1 | |
| SCHEMBL30368167 | 0.78 | TYK2 (0.67) | JAK2TYK2JAK1ANO1 | |
| SCHEMBL30368264 | 0.78 | JAK2 (0.55) | JAK2TYK2JAK1ANO1 | |
| SCHEMBL30368445 | 0.77 | NTRK1 (0.51) | JAK2TYK2JAK1ANO1MEN1 | |
| SCHEMBL13165570 | 0.76 | TYK2 (0.66) | JAK2TYK2JAK1MEN1KMT2A | |
| SCHEMBL25372494 | 0.75 | P2RX4 (0.54) | ANO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-4171744-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |